On April 3, 2025, Novartis AG announced that the FDA granted accelerated approval for Vanrafia® (atrasentan), the first selective antagonist for reducing proteinuria in IgA nephropathy, achieving a significant proteinuria reduction of 36.1% in clinical trials. This marks Novartis's third FDA approval in kidney-related therapies within the last year, enhancing treatment options for a progressive kidney disease.